bioRxiv Science⌕ Search

bioRxiv · 10.1101/378034

Sympatric and allopatric evolutionary contexts shape differential immune response in Biomphalaria / Schistosoma interaction

Abstract

Selective pressures between hosts and their parasites can result in reciprocal evolution or adaptation of specific life history traits. Local adaptation of resident hosts and parasites should lead to host-parasite systems performing better in sympatry when compared to allopatry. Between-population variations in parasite infectivity/virulence and host defence/resistance, referred to as compatibility phenotype, were often the proxy used to analyse sympatric or allopatric adaptation. Nevertheless, some reported cases exist where allopatric host-parasite systems demonstrate compatibility phenotypes similar or greater than the one observed in sympatry. In these cases, the role of local adaptation is worth considering. Here, we study the interaction between Schistosoma and its vector snail Biomphalaria in which such a discrepancy in local versus foreign compatibility phenotype has been observed. Herein, we developed an integrative approach to investigate sympatric and allopatric interaction processes and link the underlying molecular mechanisms to the resulting phenotypes. Using comparative \"omics\" approaches joined to analysis of life history traits (immune cellular response, mortality, prevalence and compatibility) we tried to bridge the gap of knowledge that exists for connecting local adaptation observations to molecular phenotypes in Schistosoma/Biomphalaria interactions.\n\nWe found that despite displaying similar prevalence phenotypes, parasite infection triggered an immune suppression in snails living in sympatry, while it activated an immune response for those living in allopatry. Dual-comparative molecular analyses revealed that parasite infection causes immune suppression in sympatry. miRNAs were used to hijack the hosts immune response, allowing sympatric parasites to initiate their developmental program earlier and more efficiently.\n\nWe show that despite having similar prevalence phenotypes, sympatric and allopatric snail-Schistosoma interactions displayed a strongly different immunobiological molecular dialogue. The ability of allopatric pathogens to adapt rapidly and efficiently to new hosts could have critical consequences on disease emergence and risk of schistosomiasis outbreaks. These observations would have important consequences in term of schistosomiasis disease control.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Portet, A., Pinaud, S., Chaparro, C., Galinier, R., Charriere, G., Allienne, J.-F., Duval, D., Gourbal, B.. 2018-07-26. Sympatric and allopatric evolutionary contexts shape differential immune response in Biomphalaria / Schistosoma interaction. https://doi.org/10.1101/378034

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy is unknown. Here, using EBV B-cell sequencing (EBV-seq), we profiled EBV+ B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV+ B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV+ B cells and shifted the reconstituted repertoire towards IgM+, minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV+ B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro, EBV+ B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV+ autoreactive B-cell repertoire contributes to sustained drug-free remission.

immunology↗

A minimal two-residue C-terminal truncation of AID in adult-onset hyper-IgM syndrome type 2 (HIGM2)

Activation-induced cytidine deaminase (AID), encoded by AICDA, facilitates class-switch recombination (CSR) and somatic hypermutation (SHM) in activated B cells. Loss of AID function causes hyper-IgM syndrome type 2 (HIGM2). While typically autosomal recessive, three C-terminal truncation variants have been reported to act in autosomal dominant manner. We describe a novel heterozygous AICDA nonsense variant, c.589G>T (p.G197*), that truncates the final two C-terminal residues of AID and results in adult-onset HIGM2. Single-cell sequencing of primary patient B cells revealed a complete block in CSR and a [~]10-fold reduction in SHM. AICDA mRNA expression was balanced between wild-type and variant alleles, yet AID protein abundance was reduced to [~]56% with normal subcellular localization. Remarkably, inducible germinal center (iGB) cultures restored CSR in purified naive patient B cells. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB platform can rescue B cells harboring heterozygous, but not homozygous, AICDA variants. These results demonstrate that even a two-amino-acid truncation at the AID C-terminus is sufficient to disrupt its function and cause HIGM2.

immunology↗

Immuno-Proteomic Age of Cardiovascular Etiology (iPACE) Signature Predicts Cardiovascular Risk in Elderly Patients

Despite advances in clinical care, cardiovascular disease (CVD) remains the leading cause of disability and mortality worldwide. While age alone is a primary risk factor for CVD, accumulating evidence suggests the immune system influences the initiation and progression of CVD pathophysiology, particularly in heart failure with preserved ejection fraction (HFpEF) and atherosclerotic CVD (ASCVD). Here, using two independent cohorts of older adults, we develop a thirty-protein signature of age based on serum immune proteomics, which correlates with HFpEF and ASCVD risk and mortality (Immuno-Proteomic Age of Cardiovascular Etiology, iPACE). We find aging-related circulating immune proteins associated with ASCVD and HFpEF-specific resilience and susceptibility that may be used as potential prognostic, diagnostic, or therapeutic targets.

immunology↗